SCHEMBL4843145

SCHEMBL4843145

N#Cc1ccc(-c2ccc(CCNC(=O)C(CC(=O)O)CC(=O)NO)cc2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP13 P45452 3/20 0.53
MMP12 P39900 2/20 0.53
ABCB1 P08183 1/20 0.50
HPGD P15428 1/20 0.50
ABCG2 Q9UNQ0 1/20 0.50
POLB P06746 1/20 0.48
MAPT P10636 1/20 0.48
MMP2 P08253 3/20 0.47
MMP9 P14780 2/20 0.47
MMP8 P22894 1/20 0.47
MMEL1 Q495T6 1/20 0.46
MMP3 P08254 4/20 0.44
MMP1 P03956 1/20 0.43
CNR1 P21554 1/20 0.42
MME P08473 1/20 0.42
EP300 Q09472 1/20 0.42
SLC1A2 P43004 1/20 0.41
KCNH2 Q12809 1/20 0.41
HDAC1 Q13547 1/20 0.40
HDAC2 Q92769 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4840357 0.87 MMEL1 (0.60) MMP2MMP9MMP8MMEL1MMP3
SCHEMBL4835085 0.86 MMP2 (0.60) MMP2MMP9MMP8MMEL1MMP3
SCHEMBL4840493 0.82 MMP2 (0.49) MMP2MMP9MMP8MMEL1MMP3
SCHEMBL6252523 0.79 MMEL1 (0.68) MMP13MMP12MMP2MMP9MMP8
SCHEMBL5891849 0.78 SMN1; SMN2 (0.48) HPGDMAPTMMP2MMP9MMP8
SCHEMBL4841370 0.77 MME (0.47) MMP2MMP9MMP8MMEL1MMP3
SCHEMBL4840456 0.77 MMEL1 (0.59) MMP13MMP12MMP2MMP9MMP8
SCHEMBL5552431 0.74 MMP2 (0.76) MMP13MMP12MMP2MMP9MMP8
SCHEMBL4840160 0.74 MMP9 (0.60) MMP2MMP9MMP8MMEL1MMP1
SCHEMBL4839093 0.73 MME (0.56) HPGDMMP8MMEHDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7105539-B2 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex ENOBIA PHARMA (CA) 2006-09-12 US claimed
US-20060135480-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex ENOBIA PHARMA (CA) 2006-06-22 US claimed
EP-1572645-A2 DERIVATIVES OF SUCCINIC AND GLUTARIC ACIDS AND ANALOGS THEREOF USEFUL AS INHIBITORS OF PHEX Enobia Pharma Inc. (CA) 2005-09-14 EP claimed
US-20040186301-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex BIOMEP INC. 2004-09-23 US claimed
WO-2004050620-A2 DERIVATIVES OF SUCCINIC AND GLUTARIC ACIDS AND ANALOGS THEREOF USEFUL AS INHIBITORS OF PHEX ENOBIA PHARMA (CA) 2004-06-17 WO claimed
US-7365091-B2 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of PHEX ENOBIA PHARMA (CA) 2008-04-29 US disclosed
US-7365091-B2 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of PHEX ENOBIA PHARMA (CA) 2008-04-29 US disclosed
US-7365091-B2 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of PHEX ENOBIA PHARMA (CA) 2008-04-29 US disclosed
US-20060287280-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of PHEX ENOBIA PHARMA (CA) 2006-12-21 US disclosed
US-7105539-B2 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex ENOBIA PHARMA (CA) 2006-09-12 US disclosed
US-20060135480-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex ENOBIA PHARMA (CA) 2006-06-22 US disclosed
EP-1572645-A2 DERIVATIVES OF SUCCINIC AND GLUTARIC ACIDS AND ANALOGS THEREOF USEFUL AS INHIBITORS OF PHEX Enobia Pharma Inc. (CA) 2005-09-14 EP disclosed
US-20040186301-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex BIOMEP INC. 2004-09-23 US disclosed
WO-2004050620-A2 DERIVATIVES OF SUCCINIC AND GLUTARIC ACIDS AND ANALOGS THEREOF USEFUL AS INHIBITORS OF PHEX ENOBIA PHARMA (CA) 2004-06-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060287280-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of PHEX GLS, SUCNR1, PGD MMP13 2582/4885MMP12 940/4885ABCB1 3147/4885
US-20040186301-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex GLS, SUCNR1, PGD MMP13 2747/4885MMP12 1111/4885ABCB1 3060/4885
US-20060135480-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex GLS, SUCNR1, GCDH MMP13 2745/4885MMP12 1107/4885ABCB1 3106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.